Wu Wei, Chen Min-hua, Fu Ying, Zhang Zhong-yi, Yang Wei, Yan Kun
Department of Ultrasound, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing 100142, China.
Beijing Da Xue Xue Bao Yi Xue Ban. 2010 Dec 18;42(6):716-21.
To investigate the efficacy of radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) according to standardized treatment strategy and individualized protocol.
A total of 468 patients of HCC underwent ultrasound/Contrast-enhanced ultrasound guided RF ablation in our department according to individualized protocol for large tumors, hypervascular tumors and tumors located adjacent to important structures in our study, of which 22 HCCs having undergone palliative RF ablation were excluded because of huge size, diffusive multiple tumors or adjacent structures invasion. The remaining 446 HCCs (680 sessions) were included and followed-up regularly to assess treatment efficiency. Of the 446 patients, 367 were male and 79 were female. 828 lesions underwent RFA. The mean size of tumors was (3.6±1.4)cm. Regular follow-up was conducted for 3-119 months. In this study, long-term outcome of various refractory tumors were also investigated.
The overall ablation success rate was 97%(803/828) 1 month after RFA. The recurrent rate was 7.2% (60/828). Base on Kaplan-Meier method, the 1-, 3- and 5-year overall survival rates after RF ablation were 85.3%, 61.3% and 47.0%, respectively. The ablation success rate of tumors larger than 3.5 cm was 90.8% (275/303). The 5-year survival rates of patients who had HCC for 3.1-5 cm and >5 cm were 45.1% and 35.9%, respectively. In this study, there were 40.3% (334/828) tumors located adjacent to important structures. The ablation success rates of these tumors located adjacent to gallbladder, diaphragm, bowel and major vessels were 93.5% (58/62), 92.5% (123/133), 92.4% (61/66) and 93.2% (68/73), respectively. The incidence of major complications was 3.1% (21/680), which included 5 intraperitoneal hemorrhages, 4 biliary injuries, 2 hemopleural effusions, 3 bowel perforations and 7 needle tract seedings. Treatment-related death occurred in 1 case of bowel perforation.
In RF ablation of refractory HCC, application of standardized treatment strategy and individualized protocol plays important roles in improving ablation success rate and minimizing potential complications. It could extend the indications of RF ablation for HCC in China.
根据标准化治疗策略和个体化方案,探讨射频消融(RFA)治疗肝细胞癌(HCC)的疗效。
本研究中,共有468例HCC患者在我科按照针对大肿瘤、高血供肿瘤及位于重要结构附近肿瘤的个体化方案接受了超声/超声造影引导下的RFA治疗,其中22例因肿瘤巨大、弥漫性多发或侵犯相邻结构而接受姑息性RFA治疗的HCC被排除。其余446例HCC(680个疗程)被纳入研究并定期随访以评估治疗效果。446例患者中,男性367例,女性79例。828个病灶接受了RFA治疗。肿瘤平均大小为(3.6±1.4)cm。进行了3至119个月的定期随访。本研究还调查了各种难治性肿瘤的长期结局。
RFA术后1个月总体消融成功率为97%(803/828)。复发率为7.2%(60/828)。根据Kaplan-Meier法,RFA术后1年、3年和5年的总生存率分别为85.3%、61.3%和47.0%。直径大于3.5 cm的肿瘤消融成功率为90.8%(275/303)。HCC直径为3.1 - 5 cm和>5 cm的患者5年生存率分别为45.1%和35.9%。本研究中,40.3%(334/828)的肿瘤位于重要结构附近。这些位于胆囊、膈肌、肠管和大血管附近的肿瘤消融成功率分别为93.5%(58/62)、92.5%(123/133)、92.4%(61/66)和93.2%(68/73)。主要并发症发生率为3.1%(21/680),其中包括5例腹腔内出血、4例胆瘘、2例血胸、3例肠穿孔和7例针道种植转移。1例肠穿孔患者发生与治疗相关的死亡。
在难治性HCC的RFA治疗中,应用标准化治疗策略和个体化方案对提高消融成功率和最大限度减少潜在并发症起着重要作用。它可以扩大RFA在中国HCC治疗中的适应证。